Andrew Orth - Chief Commercial Officer at Krystal Biotech, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Chief Commercial Officer
Issuer Symbol
KRYS on Nasdaq
All Insider Reports
All Insider Reports

There are no Buy or Sell transactions made by Andrew Orth since 23 Jan 2025

Holdings reported by Andrew Orth for Krystal Biotech, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Stock Option (Right to Buy) 37,500 $3,071,625 $81.91 09 Jun 2023 Direct Common Stock
Performance Stock Units 10,000 $1,716,554 $171.66 28 Feb 2023 Direct Common Stock
Common Stock 100 $13,000 $130.00 09 Jun 2023 Direct

Transactions reported by Andrew Orth for Krystal Biotech, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.